EA200970459A1 - Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста - Google Patents

Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста

Info

Publication number
EA200970459A1
EA200970459A1 EA200970459A EA200970459A EA200970459A1 EA 200970459 A1 EA200970459 A1 EA 200970459A1 EA 200970459 A EA200970459 A EA 200970459A EA 200970459 A EA200970459 A EA 200970459A EA 200970459 A1 EA200970459 A1 EA 200970459A1
Authority
EA
Eurasian Patent Office
Prior art keywords
opioid
dosage forms
joint introduction
agonist
antagonist
Prior art date
Application number
EA200970459A
Other languages
English (en)
Inventor
Дженнифер Риггс-Сотье
Original Assignee
Нектар Терапьютикс Ал, Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нектар Терапьютикс Ал, Корпорэйшн filed Critical Нектар Терапьютикс Ал, Корпорэйшн
Publication of EA200970459A1 publication Critical patent/EA200970459A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В данном изобретении представлены композиции, содержащие опиоидный агонист и конъюгат растворимого в воде непептидного полимера-опиоидного антагониста. Также представлены лекарственные формы и способы введения.
EA200970459A 2006-11-07 2007-11-07 Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста EA200970459A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85761006P 2006-11-07 2006-11-07
PCT/US2007/023534 WO2008057579A2 (en) 2006-11-07 2007-11-07 Dosage forms and co-administration of an opioid agonist and an opioid antagonist

Publications (1)

Publication Number Publication Date
EA200970459A1 true EA200970459A1 (ru) 2009-12-30

Family

ID=39365136

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100544A EA201100544A1 (ru) 2006-11-07 2007-11-07 Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
EA200970459A EA200970459A1 (ru) 2006-11-07 2007-11-07 Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201100544A EA201100544A1 (ru) 2006-11-07 2007-11-07 Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли

Country Status (12)

Country Link
US (1) US20100284960A1 (ru)
EP (1) EP2097083A2 (ru)
JP (1) JP2010509227A (ru)
KR (1) KR20090087442A (ru)
CN (1) CN101534827A (ru)
AU (1) AU2007317788B2 (ru)
BR (1) BRPI0718554A2 (ru)
CA (1) CA2667259A1 (ru)
EA (2) EA201100544A1 (ru)
IL (1) IL198249A0 (ru)
MX (1) MX2009004965A (ru)
WO (1) WO2008057579A2 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360284B2 (en) 2001-10-18 2006-11-02 Nektar Therapeutics Polymer conjugates of opioid antagonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
ES2534741T3 (es) * 2007-03-12 2015-04-28 Nektar Therapeutics Conjugados de oligómero-agonista opioide
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
ES2390195T3 (es) 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
WO2009029257A1 (en) 2007-08-27 2009-03-05 Theravance, Inc. Disubstituted alkyl-8-azabicyclo [3.2.1.] octane compounds as mu opioid receptor antagonists
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7691878B2 (en) 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI412360B (zh) 2007-12-11 2013-10-21 Theravance Inc 作為ｍｕ類鴉片受體拮抗劑之３－羧基丙基－胺基四氫萘衍生物及相關化合物
ES2402748T3 (es) 2007-12-11 2013-05-08 Theravance, Inc. Compuestos de aminotetralina como antagonistas del receptor de opioide mu
US8153686B2 (en) 2008-04-01 2012-04-10 Theravance, Inc. Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
MX2010011727A (es) * 2008-05-07 2010-11-30 Nektar Therapeutics Administracion oral de antagonistas opioides que actuan perifericamente.
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
US8101794B2 (en) 2008-12-10 2012-01-24 Theravance, Inc. Crystalline forms of a 3-carboxypropyl-aminotetralin compound
AU2011305161A1 (en) * 2010-09-24 2013-05-09 QRxPharma Ltd. Controlled release formulations of opioids
EA023929B1 (ru) 2010-09-30 2016-07-29 Астразенека Аб Кристаллический конъюгат налоксол-peg
US9457024B2 (en) 2011-11-07 2016-10-04 Nektar Therapeutics Compositions, dosage forms, and co-administration of an opioid agonist compound and a non-steroidal anti-inflammatory drug
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
WO2017041095A1 (en) 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
CN107406456B (zh) * 2015-12-01 2019-08-30 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
DE102015121366A1 (de) * 2015-12-08 2017-06-08 Dendropharm Gmbh Analgetische Zusammensetzungen mit Nanocarriern und ihre Verwendung
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法
CN109364078A (zh) * 2018-12-13 2019-02-22 上海市嘉定区中心医院 纳洛酮在制备镇痛药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU2002360284B2 (en) * 2001-10-18 2006-11-02 Nektar Therapeutics Polymer conjugates of opioid antagonists
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CA2758460C (en) * 2003-12-16 2014-09-23 Nektar Therapeutics Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
US20100284960A1 (en) 2010-11-11
EA201100544A1 (ru) 2012-01-30
EP2097083A2 (en) 2009-09-09
KR20090087442A (ko) 2009-08-17
CN101534827A (zh) 2009-09-16
BRPI0718554A2 (pt) 2013-11-19
WO2008057579A2 (en) 2008-05-15
IL198249A0 (en) 2009-12-24
AU2007317788B2 (en) 2013-05-02
AU2007317788A1 (en) 2008-05-15
JP2010509227A (ja) 2010-03-25
CA2667259A1 (en) 2008-05-15
WO2008057579A3 (en) 2008-12-04
MX2009004965A (es) 2009-06-05

Similar Documents

Publication Publication Date Title
EA200970459A1 (ru) Лекарственные формы и совместное введение опиоидного агониста и опиоидного антагониста
EA201170227A1 (ru) Имидазолкарбоксамиды
HK1120442A1 (en) Novel opioid antagonists
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
EA200870409A1 (ru) Антагонисты киназы pi3
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
FR15C0048I2 (fr) Anticorps antagonistes de il-17
TW200607525A (en) Compositions for delivering highly water soluble drugs
NO20092611L (no) Krystallinsk faststoff Rasagilin base
JO3492B1 (ar) تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط nep
ATE502921T1 (de) Substituierte indole
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
CY1113231T1 (el) Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
EA200802381A1 (ru) Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида
EA201492029A1 (ru) N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид
WO2010033167A3 (en) Anti-thrombin aptamer formulations and methods for use
UA103996C2 (en) Ivabradine hydrobromide
MX2009010424A (es) Formulaciones de dosificacion oral de agonista del receptor de serotina de indol organolepticamente aceptable y metodos para utilizar las mismas.